scholarly journals Metabolite Changes in Normal-Appearing Gray and White Matter Are Linked With Disability in Early Primary Progressive Multiple Sclerosis

2005 ◽  
Vol 62 (4) ◽  
pp. 569 ◽  
Author(s):  
J. Sastre-Garriga ◽  
G. T. Ingle ◽  
D. T. Chard ◽  
Lí. Ramió-Torrentà ◽  
M. A. McLean ◽  
...  
Brain ◽  
2005 ◽  
Vol 128 (6) ◽  
pp. 1454-1460 ◽  
Author(s):  
Jaume Sastre-Garriga ◽  
Gordon T. Ingle ◽  
Declan T. Chard ◽  
Mara Cercignani ◽  
Lluís Ramió-Torrentà ◽  
...  

1999 ◽  
Vol 5 (5) ◽  
pp. 313-316 ◽  
Author(s):  
S M Leary ◽  
N C Silver ◽  
V L Stevenson ◽  
G J Barker ◽  
D H Miller ◽  
...  

Patients with primary progressive multiple sclerosis may develop severe disability despite a paucity of lesions on conventional magnetic resonance imaging, raising the possibility that intrinsic changes in normal appearing white matter (NAWM) contribute to disability. This study has measured magnetisation transfer ratio (MTR), an index of tissue damage, of NAWM in 52 patients with primary progressive multiple sclerosis and 26 healthy controls. Absolute values of MTR were obtained from the genu of the corpus callosum and pons, and mean values were calculated from bilateral regions in the centrum semiovale, frontal white matter, parieto-occipital white matter and posterior limb of the internal capsule. The median MTR was lower in all regions in patients compared to controls. Median values (per cent units) were significantly lower in corpus callosum (39.73 vs 40.63; P=0.01), frontal white matter (39.11 vs 39.59; P=0.01) and centrum semiovale (37.21 vs 37.82; P50.05). This study has demonstrated small but widespread decreases in MTR in NAWM in primary progressive multiple sclerosis supporting the hypothesis that there are intrinsic changes in NAWM which may contribute to disability in this patient group.


2007 ◽  
Vol 64 (3) ◽  
pp. 411 ◽  
Author(s):  
Francesco Manfredonia ◽  
Olga Ciccarelli ◽  
Zhaleh Khaleeli ◽  
Daniel J. Tozer ◽  
Jaume Sastre-Garriga ◽  
...  

2020 ◽  
Author(s):  
Pavel Filip ◽  
Michal Dufek ◽  
Silvia Mangia ◽  
Shalom Michaeli ◽  
Martin Bares ◽  
...  

Abstract Background: The research of primary progressive multiple sclerosis (PPMS) has not been able to capitalize on recent progresses in advanced MRI protocols searching for disease-specific microstructural changes. Methods: Conventional free precession T1 and T2, and rotating frame adiabatic T1ρ and T2ρ maps in combination with diffusion weighted parameters were acquired in 13 PPMS patients and 13 age and sex-matched controls.Results: T1ρ, a marker of crucial relevance for PPMS due to its sensitivity to neuronal loss, revealed large-scale changes in mesiotemporal structures, sensorimotor cortex and cingulate, in combination with diffuse alterations in the white matter and cerebellum. T2ρ, particularly sensitive to local tissue background gradients and thus indicator of iron accumulation, concurred with similar topography of damage, but of lower extent. Moreover, these adiabatic protocols completely dwarfed the outcomes of both conventional T1 and T2 maps and diffusion tensor/kurtosis approaches –methods previously implicated in the MRI research of PPMS.Conclusion: This study introduces adiabatic T1ρ and T2ρ as elegant markers confirming large-scale cortical grey matter, cerebellar and white matter alterations in PPMS invisible to other in vivo biomarkers.


Brain ◽  
2019 ◽  
Vol 142 (9) ◽  
pp. 2787-2799 ◽  
Author(s):  
Colm Elliott ◽  
Shibeshih Belachew ◽  
Jerry S Wolinsky ◽  
Stephen L Hauser ◽  
Ludwig Kappos ◽  
...  

Chronic active and slowly expanding/evolving lesions with smouldering inflammation are neuropathological correlates of progressive multiple sclerosis. Elliott et al. report that T1-weighted measures of chronic lesion activity predict clinically progressive multiple sclerosis, may represent a longitudinal neuroimaging correlate of smouldering demyelination and axonal loss, and are reduced by ocrelizumab.


2018 ◽  
Vol 56 (7) ◽  
pp. 80-84

▼Ocrelizumab (Ocrevus - Roche Registration GmbH) has received marketing authorisation approval from the European Medicines Agency (EMA) for the treatment of adults with multiple sclerosis.1,2 It is the first drug to be licensed for use in early primary progressive multiple sclerosis and relapsing forms of multiple sclerosis. Here, we review the evidence for the safety and effectiveness of ocrelizumab.


Sign in / Sign up

Export Citation Format

Share Document